Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2350
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer ; volume:4 ; number:1 ; day:11 ; month:8 ; year:2003 ; pages:1-6 ; date:12.2003
BMC medical genetics ; 4, Heft 1 (11.8.2003), 1-6, 12.2003
- Creator
-
Hamel, Nancy
- Contributor
-
Kotar, Kimberley
Foulkes, William D.
SpringerLink (Online service)
- DOI
-
10.1186/1471-2350-4-7
- URN
-
urn:nbn:de:1111-2016021831756
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:31 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hamel, Nancy
- Kotar, Kimberley
- Foulkes, William D.
- SpringerLink (Online service)
Other Objects (12)
BRCA1 founder mutations do not contribute to increased risk of gastric cancer in the Polish population
Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control
High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population
High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients
BRCA1 4153delA founder mutation in Russian ovarian cancer patients
TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival
Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals
Recurrent and founder mutations in the Netherlands: the cardiac phenotype of DES founder mutations p.S13F and p.N342D
BRCA mutations: screening for germ-line founder mutations among early-onset Syrian breast cancer patients
A case–control study of BRCA1 founder mutations 185delAG and 5382insC in a cohort of Egyptian ovarian cancer patients using pyrosequencing technique
Frequent Mutations in Natural Killer/T Cell Lymphoma
BRCA1 and BRCA2 mutations in central and southern Italian patients
BRCA1 founder mutations do not contribute to increased risk of gastric cancer in the Polish population
Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control
High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population
High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients
BRCA1 4153delA founder mutation in Russian ovarian cancer patients
TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival
Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals
Recurrent and founder mutations in the Netherlands: the cardiac phenotype of DES founder mutations p.S13F and p.N342D
BRCA mutations: screening for germ-line founder mutations among early-onset Syrian breast cancer patients
A case–control study of BRCA1 founder mutations 185delAG and 5382insC in a cohort of Egyptian ovarian cancer patients using pyrosequencing technique
Frequent Mutations in Natural Killer/T Cell Lymphoma
BRCA1 and BRCA2 mutations in central and southern Italian patients
BRCA1 founder mutations do not contribute to increased risk of gastric cancer in the Polish population
Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control
High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population
High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients
BRCA1 4153delA founder mutation in Russian ovarian cancer patients
TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival
Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals
Recurrent and founder mutations in the Netherlands: the cardiac phenotype of DES founder mutations p.S13F and p.N342D
BRCA mutations: screening for germ-line founder mutations among early-onset Syrian breast cancer patients
A case–control study of BRCA1 founder mutations 185delAG and 5382insC in a cohort of Egyptian ovarian cancer patients using pyrosequencing technique
Frequent Mutations in Natural Killer/T Cell Lymphoma